Chicago, ILNCT05838599Now EnrollingIRB Ready

Mycosis Fungoides Clinical Trial in Chicago, IL

Access cutting-edge mycosis fungoides treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access mycosis fungoides specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related mycosis fungoides treatment provided free

Apply for This Chicago Location

Check if you qualify for this mycosis fungoides clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Mycosis Fungoides Study in Chicago

Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently pursued management option for CTCL, especially in patients with more advanced skin disease. Imiquimod stimulates a Th1 lymphocyte response with increased IL-2 and IFN-α, but also induces IFN-α, TNF-α, IL-1α, IL-6, and IL-8, thereby bridging both innate and adaptive immunity. Dosing of both radiotherapy (RT) and imiquimod are based on standard-of-care doses/frequencies for CTCL. The reason imiquimod topical is given for a week before giving RT is to prime innate immune activity for when RT is delivered. It is believed that this serves as an adjuvant for the CD8+ antitumor response generated by RT. The primary aim of this study is to assess the safety and efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Patients must have confirmed stage IA-IIB mycosis fungoides.
Patients must be 18-90 years of age.
Patients must have failed at least one standard therapy for MF.
Patients must have active, but stable disease for \>6 months.
Patients must have 4 or more discrete MF lesions with at least 2 of them with minimum combined surface area of \>50cm2.
POCBP must have a negative pregnancy test prior to registration on study.
Patients must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Patients who are on current systemic or topical CTCL therapy, unless stable on the treatment for \>6 months.
Patients who have received antibiotic therapy within 4 weeks of study enrollment.
Patients who are pregnant or nursing. Pregnant people are excluded from this study because IMQ is an agent with potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the gestational parent with IMQ, breastfeeding should be discontinued if the parent is treated with IMQ.
Patients with psychiatric illness/social situations that would limit compliance with study requirements.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT05838599) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Mycosis Fungoides Treatment Options in Chicago, IL

If you're searching for mycosis fungoides treatment options in Chicago, IL, this clinical trial (NCT05838599) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced mycosis fungoides specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all mycosis fungoides clinical trials near you to find additional studies recruiting in your area.

More Osteogenesis Imperfecta Trials in Chicago, IL

See all osteogenesis imperfecta clinical trials recruiting in Chicago — not just this study.

Browse Osteogenesis Imperfecta Trials in Chicago →

Browse More Trials by Condition

Osteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL